Pfizer could begin manufacturing Paxlovid in China through a local partner within three to four months following moves by Beijing to provide the clearances required to produce and supply the Covid-19 drug in the country.
在manbetx3.0 政府给予辉瑞(Pfizer)本地生产和供应奈马特韦片/利托那韦片（商品名：Paxlovid）的许可后，辉瑞可在三到四个月内通过一家manbetx3.0 合作伙伴开始在manbetx3.0 本地生产这种新冠口服药。
您已阅读9%（311字），剩余91%（3018字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。